FDA Guidance Rewards Engineering Out The Psychedelic Experience

The U.S. Food and Drug Administration’s final guidance on psychedelic drug development (July 2026) directs sponsors to record psychoactive effects as adverse events, even when those effects are hypothesized to drive the therapeutic response, and to staff dosing sessions with two monitors. Read together, these provisions incentivize sponsors to remove the subjective experience, which eliminates both the recorded harm and the dominant labor cost. Billing architecture reinforces the incentive, and recent pharmaceutical acquisitions and capital investments follow the same gradient toward less experience and shorter sessions. Because current Phase 3 trials hold psychological support constant across arms, none can test whether context matters, and the state programs that generate the relevant variation can neither bill for their services nor fund their own evaluation. This paper identifies three critical dimensions of psychedelic care that sit beyond what regulatory and payment structures can currently register, and closes with three recommendations. Left as is, the field may settle whether the experience matters by never testing it.